A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Benign Prostatic Hyperplasia
Intervention: MK0906, finasteride / Duration of Treatment: 48 weeks (Drug); Comparator: placebo / Duration of Treatment: 48 weeks (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
The purpose of this trial is to determine the efficacy and safety of an investigational drug
in patients with benign prostatic hyperplasia.
Clinical Details
Official title: MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Change from baseline in the International Prostate Symptom Score
Secondary outcome: Change from baseline in QOL - indexChange from baseline in maximum urinary flow rate, % Change from baseline in Prostate volume
Eligibility
Minimum age: 50 Years.
Maximum age: 79 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Patients with benign prostatic hyperplasia
Exclusion Criteria:
- Patients who are suspected to be suffering from prostatic cancer
Locations and Contacts
Call for Site Information, Tokyo, Chuoku 103-8416, Japan
Additional Information
Starting date: January 2004
Last updated: June 2, 2006
|
